AN OVERVIEW OF THE PHARMACEUTICAL PROFILE OF RIVAROXABAN

The first approved orally active direct inhibitor of factor Xa is rivaroxaban (RIV). The main topics of this review include the pharmacological profile, physicochemical properties, methods to improve water solubility and pharmaceutical dosage forms developed in various recent studies. New approaches have been designed to increase the low solubility of rivaroxaban. These technologies, which range from conventional dosage forms to drug delivery systems with nanoparticles, can potentially enhance bioavailability and thus therapeutic efficacy. The literature search revealed that several methodologies were applied depending on the aim of the study, since the physicochemical properties of RIV allow its incorporation into different pharmaceutical systems